Pharmaceutical intermediates
Remibrutinib Intermediates
3 pharmaceutical intermediates for Remibrutinib. Indication: Chronic Urticaria; Multiple Sclerosis.
About Remibrutinib
- Originator
- Novartis Pharmaceuticals Corp
- Indication
- Chronic Urticaria; Multiple Sclerosis
Available intermediates
3 intermediates currently listed for Remibrutinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 5-Fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline | 1418128-33-2 | / | / |
| tert-butyl 2-(4-amino-6-chloropyrimidin-5-yloxy)ethylmethylcarbamate | 1787294-51-2 | / | / |
| 4-cyclopropyl-2-fluoro-N-(5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzamide | 1787294-47-6 | / | / |
Other programs under R
Building toward Remibrutinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →